Muccino, David R. et al
"Design and rationale of two phase 3 randomised controlled trials (COUGH-1 and COUGH-2) of gefapixant, a P2X3 receptor antagonist, in refractory or unexplained chronic cough." ERJ Open Research
6.4
(2020):
00284-2020.
Web. 08 Dec. 2024.
